Odd Terje Brustugun

9.0k citations

136 papers · 2.9k indexed · h-index 30

Oncology top 2%
- Lung Cancer Research Studies 34
- Cancer Immunotherapy and Biomarkers 13
- Global Cancer Incidence and Screening 10
- Colorectal Cancer Treatments and Studies 8
Cancer Research top 2%
- Cancer Genomics and Diagnostics 15
Pulmonary and Respiratory Medicine top 2%
- Lung Cancer Treatments and Mutations 73
- Lung Cancer Diagnosis and Treatment 41
Immunology top 10%
Molecular Biology top 10%
Epidemiology
- Neuroendocrine Tumor Research Advances 9

Co-authors: Åslaug Helland Marius Lund‐Iversen Ann Rita Halvorsen Steinar Solberg Stein Ove Døskeland Bjørn Møller Bjørn Henning Grønberg Kari E. Fladmark
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: Journal of Biological Chemistry (1 paper)Journal of Clinical Oncology (6 papers)SHILAP Revista de lepidopterología (1 paper)
Partner nations: Norway Sweden Denmark

In The Last Decade

Odd Terje Brustugun

132 papers receiving 2.9k citations

Peers

Countries citing papers authored by Odd Terje Brustugun

Since Specialization

Citations

This map shows the geographic impact of Odd Terje Brustugun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Odd Terje Brustugun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Odd Terje Brustugun more than expected).

Fields of papers citing papers by Odd Terje Brustugun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Odd Terje Brustugun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Odd Terje Brustugun. The network helps show where Odd Terje Brustugun may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Odd Terje Brustugun, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Odd Terje Brustugun Line = papers co-authored together Odd Terje Brustugun links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial Journal of Thoracic Oncology ·Bjørn Henning Grønberg,Kristin Toftaker Killingberg,Øystein Fløtten,Maria Moksnes Bjaanæs,Odd Terje Brustugun,Tesfaye Madebo,Seppo W. Langer,Signe Lenora Risumlund,Tine Schytte,Nina Helbekkmo,Kirill Neumann,Øyvind Yksnøy,Jens Engleson,Sverre Fluge,Thor Naustdal,Liv Giske,Jan Nyman,Georgios Tsakonas,Tarje Onsøien Halvorsen	2025	1
2	Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study Frontiers in Oncology ·Johanne Elise Nyen,Andrew Booth,Øyvind Husby,Christoffer Bugge,Ingrid Engebretsen,Francisco Oteiza,Åslaug Helland,Lars Fjellbirkeland,Odd Terje Brustugun,Bjørn Henning Grønberg	2025	2
3	Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer Clinical and Experimental Medicine ·Anne Pernille Harlem Dyrbekk,Abdirashid Warsame,Pål Suhrke,Marianne Odnakk Ludahl,Nermin Zecic,Joakim Oliu Moe,Marius Lund‐Iversen,Odd Terje Brustugun	2024	2
4	Evaluation of sex inequity in lung-cancer-specific survival Acta Oncologica ·Dan Lærum,Trond‐Eirik Strand,Odd Terje Brustugun,Frode Gallefoss,Ragnhild Sørum Falk,Michael T. Durheim,Lars Fjellbirkeland	2024	2
5	KontRASt-02: A phase III trial investigating the efficacy and safety of the KRAS ^G12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C -mutated NSCLC. Journal of Clinical Oncology ·Federico Cappuzzo,Gilberto de Castro,Jin‐Hyoung Kang,Yi‐Long Wu,Odd Terje Brustugun,Parneet Cheema,Taofeek K. Owonikoko,Anne-Sophie Longin,Aislyn Boran,Jiawei Duan,Rafael Caparica,Herbert H. Loong	2023	8
6	“Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer” Diagnostic Pathology ·Anne Pernille Harlem Dyrbekk,Abdirashid Warsame,Pål Suhrke,Marianne Odnakk Ludahl,Joakim Oliu Moe,Inger Johanne Zwicky Eide,Marius Lund‐Iversen,Odd Terje Brustugun	2023	2
7	Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer Cancers ·Zeinab Kosibaty,Odd Terje Brustugun,Inger Johanne Zwicky Eide,Georgios Tsakonas,Oscar Grundberg,Luigi De Petris,Marc McGowan,Per Hydbring,Simon Ekman	2022	6
8	Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients Translational Lung Cancer Research ·Andrey Alexeyenko,Odd Terje Brustugun,Inger Johanne Zwicky Eide,Radosveta Gencheva,Zeinab Kosibaty,Yi Chun Lai,Luigi De Petris,Georgios Tsakonas,Oscar Grundberg,Bo Franzén,Kristina Viktorsson,Rolf Lewensohn,Per Hydbring,Simon Ekman	2022	4
9	Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma Frontiers in Oncology ·Anand Khadse,Vilde Drageset Haakensen,Laxmi Silwal‐Pandit,Julian Hamfjord,Patrick Micke,Johan Botling,Odd Terje Brustugun,Ole Christian Lingjærde,Åslaug Helland,Elin H. Kure	2022	3
10	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer Lung Cancer ·Sanjay Popat,Odd Terje Brustugun,J. Cadranel,Enriqueta Felip,Marina Chiara Garassino,Frank Griesinger,Åslaug Helland,Maximilian J. Hochmair,M. Pérol,Nawal Bent‐Ennakhil,Christian Kruhl,Silvia Novello	2021	13
11	Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study) Lung Cancer ·Inger Johanne Zwicky Eide,Åslaug Helland,Simon Ekman,Anders Mellemgaard,Karin Holmskov Hansen,Saulius Cicėnas,Jussi Koivunen,Bjørn Henning Grønberg,Odd Terje Brustugun	2020	43
12	1683P SARS-CoV-2 infection and lung cancer management in Europe Annals of Oncology ·Abed Agbarya,Alfredo Addeo,A. Charpidou,(unknown),Kristof Cuppens,Odd Terje Brustugun,Mirjana Rajer,Marija Magdalena Jakopović,Mihai Vasile Marinca,Adam Płużański	2020	2
13	Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015–2016 BMC Cancer ·Yngvar Nilssen,Odd Terje Brustugun,Morten Eriksen,Erik Skaaheim Haug,Bjørn Naume,Bjørn Møller	2020	15
14	Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer Clinical Cancer Research ·Tom Dønnem,Sigurd M. Hald,Erna‐Elise Paulsen,Elin Richardsen,Samer Al‐Saad,Thomas K. Kilvær,Odd Terje Brustugun,Åslaug Helland,Marius Lund‐Iversen,Mette Poehl,Karen Ege Olsen,Henrik J. Ditzel,Olfred Hansen,Khalid Al‐Shibli,Yury Kiselev,Torkjel M. Sandanger,Sigve Andersen,Francesco Pezzella,Roy M. Bremnes,Lill‐Tove Busund	2015	252
15	Human papilloma virus detection and typing in 334 lung cancer patients Acta Oncologica ·Camilla Sagerup,Dag André Nymoen,Ann Rita Halvorsen,Marius Lund‐Iversen,Åslaug Helland,Odd Terje Brustugun	2014	18
16	Associations between TS, TTF-1, FR-α, FPGS, and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin or Gemcitabine Plus Carboplatin as First-Line Chemotherapy Journal of Thoracic Oncology ·Bjørn Henning Grønberg,Marius Lund‐Iversen,Erik H. Strøm,Odd Terje Brustugun,Helge Scott	2013	37
17	Dosimetric impact of a frame-based strategy in stereotactic radiotherapy of lung tumors Acta Oncologica ·Einar Waldeland,Christina Ramberg,Marius Røthe Arnesen,Åslaug Helland,Odd Terje Brustugun,Eirik Malinen	2012	5
18	Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer BMC Cancer ·Ane Kongsgaard,Marius Lund‐Iversen,G Berge,Odd Terje Brustugun,Steinar Solberg,Gunhild M. Mælandsmo,Kjetil Boye	2012	16
19	B4-05: Development of a serum marker panel for early lung cancer detection and treatment response assessment using the proximity-ligation assay (PLA) Journal of Thoracic Oncology ·Odd Terje Brustugun,Quynh‐Thu Le,Albert C. Koong,Åslaug Helland,Paal Brunsvig,Ron Davis,Simon Fredriksson	2007	1
20	Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix International Journal of Cancer ·Heidi Lyng,Marzieh Beigi,Debbie Hege Svendsrud,Odd Terje Brustugun,Trond Stokke,Gunnar B. Kristensen,Kolbein Sundfør,Ane Skjønsberg,Paula M. De Angelis	2004	20

About Odd Terje Brustugun

Odd Terje Brustugun is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 136 papers that have together received 2.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (73 papers), Lung Cancer Diagnosis and Treatment (41 papers), Lung Cancer Research Studies (34 papers), Cancer Genomics and Diagnostics (15 papers), Cancer Immunotherapy and Biomarkers (13 papers), Global Cancer Incidence and Screening (10 papers), Neuroendocrine Tumor Research Advances (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). The work is most often cited by research in Oncology (1.4k citations), Cancer Research (680 citations) and Pulmonary and Respiratory Medicine (1.3k citations). Odd Terje Brustugun has collaborated with scholars based in Norway, Sweden and Denmark. Frequent co-authors include Åslaug Helland, Marius Lund‐Iversen, Ann Rita Halvorsen, Steinar Solberg, Stein Ove Døskeland, Bjørn Møller, Bjørn Henning Grønberg, Kari E. Fladmark, Inger Øynebråten and Yngvar Nilssen. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact